Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy (SBRT) for Oligo-Progressive Non-Small Cell Lung Cancer (NSCLC)

NCT07619599 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07619599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07619599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy (SBRT) for Oligo-Progressive Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
September 14, 2026
Completion date
December 22, 2028
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic lung non-small cell carcinoma, metastatic malignant neoplasm in the brain, oligoprogressive lung non-small cell carcinoma, stage iv lung cancer ajcc v8